Published in Clin Microbiol Rev on January 01, 2016
Maternal Immunoreactivity to Herpes Simplex Virus 2 and Risk of Autism Spectrum Disorder in Male Offspring. mSphere (2017) 1.21
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Epigenetics and Genetics of Viral Latency. Cell Host Microbe (2016) 0.79
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther (2016) 0.79
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med (2016) 0.77
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 9.21
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med (2007) 7.79
Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med (2008) 7.49
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep (2015) 6.63
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 6.23
Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med (1981) 5.44
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature (1987) 3.77
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
The genome sequence of herpes simplex virus type 2. J Virol (1998) 3.39
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe (2008) 3.02
Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS (2002) 2.93
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One (2015) 2.68
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis (2005) 2.55
Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol (1985) 2.54
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med (2014) 2.36
The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis (1997) 2.31
Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis (2009) 2.23
The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis (2007) 2.14
Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA (1994) 2.03
Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis (2005) 1.91
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1991) 1.89
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis (2012) 1.86
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA (2011) 1.85
The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem (2008) 1.83
Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis (2013) 1.82
Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis (1979) 1.82
A review of the identification and titration of antibodies to herpes simplex viruses type 1 and type 2 in human sera. Cancer Res (1973) 1.81
Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis (2013) 1.80
Performance of the focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. J Clin Microbiol (2003) 1.76
Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis (2002) 1.75
Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol (2010) 1.71
Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med (1999) 1.67
Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis (2004) 1.65
Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med (2009) 1.60
A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med (2009) 1.56
Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis (1998) 1.55
Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A (2010) 1.49
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. Obstet Gynecol (2007) 1.43
Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis (2003) 1.38
Evolution and diversity in human herpes simplex virus genomes. J Virol (2013) 1.35
Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis (2008) 1.35
Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 1.34
Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis (2005) 1.34
Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect (2007) 1.32
Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sex Transm Infect (2009) 1.32
Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years--United States, 1988 to 2010. Sex Transm Dis (2013) 1.30
Performance of commercial herpes simplex virus type-2 antibody tests using serum samples from Sub-Saharan Africa: a systematic review and meta-analysis. Sex Transm Dis (2011) 1.29
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med (2014) 1.24
Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis (2011) 1.23
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS (2011) 1.22
Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS (2009) 1.21
Restriction endonuclease analysis of DNA from genital isolates of herpes simplex virus type 2. Infect Immun (1982) 1.19
Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. JAMA (1990) 1.18
Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect (2009) 1.17
Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol (2007) 1.16
Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. Int J STD AIDS (2010) 1.15
Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis (1998) 1.13
Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife (2013) 1.12
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis (1997) 1.10
High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis (2011) 1.09
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09
A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sex Transm Infect (2009) 1.06
Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis (2010) 1.03
Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries. Sex Transm Infect (2011) 1.03
Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine (2014) 1.03